This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Intranasal Oxytocin and Vasopressin on Social Behavior

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
Hebrew University of Jerusalem
Information provided by:
Hadassah Medical Organization Identifier:
First received: February 3, 2011
Last updated: April 7, 2011
Last verified: April 2011
The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and altruism in a healthy population of student controls.

Condition Intervention
Healthy Drug: Oxytocin Drug: Arginine Vasopressin Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Basic Science
Official Title: Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • allocations of monetary units [ Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo ]
    Participants will make decisions regarding the allocation of monetary units between themselves and other participants. We will measure the quantity of monetary units kept for themselves vs. given to other participants

Secondary Outcome Measures:
  • mood as measured via the visual analog scale [ Time Frame: approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo ]

Estimated Enrollment: 150
Study Start Date: April 2011
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vasopressin
vasopressin condition
Drug: Arginine Vasopressin
one-time intranasal administration, 20 International Units, 5 puffs in each nostril
Experimental: oxytocin
oxytocin condition (syntocinon)
Drug: Oxytocin
one-time intranasal administration, 24 International Units, 5 puffs for each nostril
Other Name: syntocinon
Placebo Comparator: placebo Drug: placebo
contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril


Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy controls

Exclusion Criteria:

  • Past or present psychiatric, neurological, endocrinological or severe chronic medical illness.
  • Use of medications or drugs that would interfere with study results. This includes steroids, medications for psychiatric symptoms like anxiety or depression, stimulants, and medications for high blood pressure. Participants will be asked to tell the investigators of any medications or drugs that they are taking. The investigators will consider the drug interactions with oxytocin and vasopressin prior to study, and participants will not be able to participate in the study if the drug interactions could be dangerous.
  • history of drug or alcohol addiction
  • Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women who are pregnant or nursing are excluded from this protocol. All females will have a pregnancy test performed no more than 24 hours before each drug administration and will not be able to participate if the pregnancy test is positive.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01296269

Contact: David Mankuta, MD 972-2-6776484
Contact: Salomon Israel, MA 972-524789754

Hadassah University Medical Organization Recruiting
Jerusalem, Israel
Contact: David Mankuta, MD    972-2-6776484   
Contact: Salomon Israel, MA    972-52-4789754   
Principal Investigator: David Mankuta, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Hebrew University of Jerusalem
Principal Investigator: David Mankuta, MD Hadassah University Medical Organization
  More Information

Responsible Party: David Mankuta MD, Hadassah Ein-Kerem - obstetrics and gynecology Identifier: NCT01296269     History of Changes
Other Study ID Numbers: OXTandAVP-HMO-CTIL
Study First Received: February 3, 2011
Last Updated: April 7, 2011

Keywords provided by Hadassah Medical Organization:
social cognition
decision making
social decision making

Additional relevant MeSH terms:
Arginine Vasopressin
Reproductive Control Agents
Physiological Effects of Drugs
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents processed this record on September 21, 2017